CMS Changes The Dictionary: Medicaid ‘Best Price’ Could Soon Mean Many Things

Value and outcomes-based purchasing agreements could see a boost under proposed Medicaid rule that CMS says will make it easier for manufacturers to experiment different contracting structures in the commercial health insurance market. CMS says the intent of these agreements is to lower drug prices for commercial payers, but the government acknowledges this is not guaranteed, and health policy experts worry both private payers and Medicaid could end up paying higher prices if the proposal is finalized.

best price concept 3d illustration isolated on white background
New Medicaid proposed rule would change best price reporting to accommodate value-based purchasing deals • Source: Shutterstock

Drug manufacturers will get a long-desired change to Medicaid best price reporting requirements under a new Centers for Medicare and Medicaid Services proposed rule that is designed to make it easier for manufacturers to enter into value-based drug pricing contracts with commercial payers, with the US government arguing the rule will be particularly useful for one-time use gene therapies with high upfront costs.

CMS says the change might lead to lower drug prices in the private sector while preserving Medicaid’s ability to get...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medicaid

More from Government Payers

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By 

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

Saving Part D: US Medicare Advisors Sound The Alarm

 

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By 

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.